ManalFAbdelmalekMDMD, MPH

Gastroenterology • Rochester, MN

Hepatology & Liver Transplantation

Professor of Medicine, Mayo Clinic, Rochester, MN

Join to view full profile

Dr. Abdelmalek is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Abdelmalek's full profile

Already have an account?

Office
200 1st Street SW
Rochester, MN 55905

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Gastroenterology, 1996 - 1998
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1992 - 1995
University of Missouri Kansas City School of MedicineClass of 1992

Certifications & Licensure

AZ State Medical License 1996 - Present
MN State Medical License 2022 - 2025
NC State Medical License 2006 - 2023
FL State Medical License 1998 - 2011
American Board of Internal Medicine Gastroenterology
American Board of Internal Medicine Transplant Hepatology

Awards, Honors, & Recognition

Most Compassionate Doctor American Registry
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Insulin Resistance in Nonalcoholic Fatty Liver Disease: A Case Control Study Start of enrollment: 2007 Jul 01
Terminated
Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) Start of enrollment: 2009 Apr 01
Terminated
Phase 4
PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)
COMPLETED
PHASE2
Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2 Start of enrollment: 2009 Dec 02
Completed
Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance Biomarkers in Nonalcoholic Fatty Liver Disease Start of enrollment: 2013 Oct 01
Terminated
Phase 2
JKB-121 for the Treatment of Nonalcoholic Steatohepatitis Start of enrollment: 2015 Aug 01
Completed
Phase 2
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis Start of enrollment: 2015 Jun 01
Completed
Phase 2
Statins for the Treatment of NASH Start of enrollment: 2023 Jan 25
RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study Start of enrollment: 2021 May 11
RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

6 citations
Alterations in DNA methylation associate with fatty liver and metabolic abnormalities in a multi-ethnic cohort of pre-teenage children.
Cynthia A Moylan, Alisha M Mavis, Dereje Jima, Rachel Maguire, Mustafa Bashir
Epigenetics. 2022-11-01
29 citations
Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to othe...
Tinsay A Woreta, Mark L Van Natta, Mariana Lazo, Arunkumar Krishnan, Brent A Neuschwander-Tetri
Plos One. 2022-01-01
68 citations
Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis.
Rohit Loomba, Vlad Ratziu, Stephen A. Harrison, Stefanie C. McFarlane, Nobuharu Tamaki
Gastroenterology. 2021-11-22

Journal Articles

The Lancet Child & Adolescent Health
Arun Sanyal, Stephen A Harrison, Edgar D Charles, Stephanie Noviello, Manal F Abdelmalek, Eric J Lawitz, Rohit Loomba, The Lancet

Press Mentions

5 Surprising Things to Know About Fatty Liver DiseaseMay 6th, 2022
Global Liver Institute’s International NASH Day 2021 Attracts Broad SupportJune 18th, 2021
Inventiva Achieves a Major Milestone by Completing Patient Recruitment for Its Phase IIb Clinical Study with Lanifibranor in NASHSeptember 4th, 2019
Join now to see all

Grant Support

Impact Of Fructose On Metabolism, Energy Homeostasis And MR Biomarkers In NafldNational Institute Of Diabetes And Digestive And Kidney Diseases2012
Hyperinsulinemia And Insulin Resistance In Fatty LiverNational Institute Of Diabetes And Digestive And Kidney Diseases2006–2009
Insulin Resistance In Nonalcoholic Fatty Liver Disease A Case Control StudyNational Center For Research Resources2006–2007
Trial Of Betaine In PTS With Nonalcoholic SteatohepatisNational Center For Research Resources2005–2007
Hyperinsulinemia And Insulin Resistance In Fatty LiverNational Institute Of Diabetes And Digestive And Kidney Diseases2005
Trial Of Betaine In PTS With Nonalcoholic SteatohepatitisNational Center For Research Resources2004